This is a retrospective, single-arm, multicenter clinical study designed to evaluate the efficacy and safety of DEB-BACE (Drug-Eluting Bead Bronchial Artery Chemoembolization) in the treatment of primary lung cancer.
1. Age ≥ 18 years old, gender unrestricted; 2. Diagnosed with primary lung cancer based on the Primary Lung Cancer Diagnosis and Treatment Guidelines (2022 Edition) through histopathological examination; 3. At least one measurable lesion (evaluated according to RECIST 1.1 criteria); 4. Previously received at least one DEB-BACE treatment; 5. ECOG PS score ≤ 2; 6. Complete patient case records.
1. Presence of extensive and uncontrolled extrapulmonary brain metastasis lesions; 2. Irreversible coagulation dysfunction within a short period of time; 3. Uncontrollable hypertension, diabetes, or significant cardiovascular diseases with obvious symptoms; 4. Allergy to contrast agent; 5. Pregnant or lactating women; 6. Patients whose condition, as judged by the investigator, poses a serious threat to patient safety or hinders their participation in the study.
Primary Lung Cancer
Other
Retrospective
DEB-BACE
Procedure/SurgeryDrug-Eluting Bead microspheres used for embolization: Drug-Eluting Bead microspheres 1tube was loaded and adsorbed chemotherapy. End point of embolization: stagnation of blood flow in tumor feeding artery
ORR
ORR is defined as the percentages of patients, relative to the total of enrolled subjects, achieving a complete (CR) or partial (PR) response, according to mRECIST 1.1 criteria
PFS
PFS was defined as the time from recruitment to the first documented progressive disease (PD) or death due to any cause, whichever occurred first.
OS
The time from recruitment to death due to any cause
Click on the lead sponsor to view all of their trials.
Gang Wu, MD
Lead sponsor
The First Affiliated Hospital of Zhengzhou University
Sponsor institution
This trial is not recruiting at the moment. You can still explore other options:
